Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02375204

Recruitment Status : Active, not recruiting

First Posted : March 2, 2015

Last Update Posted : March 17, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

National Cancer Institute (NCI)

European Organisation for Research and Treatment of Cancer - EORTC

Movember Foundation

Institute of Cancer Research (ICR), United Kingdom

Cancer Research UK

UNICANCER

Irish Group CTI

Information provided by (Responsible Party):

Alliance for Clinical Trials in Oncology

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 2024
Estimated Study Completion Date :	June 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tan YY, Al-Bubseeree B, Irvine D, MacDonald G, McQuaker G, Parker A, Waterston A, White J. High-Dose Chemotherapy in Relapsed or Refractory Metastatic Germ-Cell Cancer: The Scotland Experience. Clin Genitourin Cancer. 2019 Apr;17(2):125-131. doi: 10.1016/j.clgc.2018.11.013. Epub 2018 Nov 17.

To Top